Please provide your email address to receive an email when new articles are posted on . MIAMI — An anti-complement C5 therapy had no different effect on geographic atrophy lesion size than sham ...
Complement C5a is a known mediator of inflammatory and neuropathic pain. In a new study, patients with NMOSD who were in remission and healthy controls were asked to rate their pain on a visual analog ...
Alnylam Scientists Present Pre-clinical Data with ALN-CC5, an RNAi Therapeutic Targeting Complement Component C5 for the Treatment of Complement-Mediated Diseases – New Research Presented at 6 th ...
The complement system is a crucial part of innate immune defenses against invading pathogens. The blood-meal of the tick Rhipicephalus pulchellus lasts for days, and the tick must therefore rely on ...
Dysfunction of the complement system plays an important role in the pathogenesis of renal diseases. Complement inhibitors, such as C5 inhibitors, have shown efficacy in clinical trials, but may no be ...
NEW YORK--(BUSINESS WIRE)-- IVERIC bio, Inc. (Nasdaq: ISEE) today announced initial topline data confirming that Zimura® (avacincaptad pegol), the Company’s complement factor C5 inhibitor, met its ...
Left untreated, PNH could cause death in about half of patients within 10 years of diagnosis. The primary cause of PNH-related mortality is thromboembolic events. A host of anti-complement strategies, ...
CAMBRIDGE, Mass.--(BUSINESS WIRE)--Ra Pharmaceuticals, Inc. (Nasdaq:RARX) today announced the presentation of scientific data at the 23 rd Congress of the European Hematology Association (EHA), June ...
BEIJING & CAMBRIDGE, Mass.--(BUSINESS WIRE)--CANbridge Pharmaceuticals, Inc. (“CANbridge,” stock code 1228.HK), a China-based global biopharmaceutical company committed to the research, development ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback